ObsEva SA started trading on the SIX Swiss Exchange

• Trading of ObsEva's shares on SIX Swiss Exchange started on 13 July 2018 under the ticker symbol 'OBSN'

• Reference price at CHF 15.00 per share
• ObsEva with unique pipeline of novel and potential best-in class therapeutics to address serious conditions with a high unmet medical need affecting millions of women

Geneva, Switzerland and Boston, MA - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, announced that its shares will be listed and start trading on 13 July 2018 under the "International Reporting Standard" on SIX Swiss Exchange. The issued share capital comprises 45'381'252 registered shares with a nominal value of 1/13 of CHF 1 each. The reference price is CHF 15.00 per share, corresponding to a market capitalization of CHF 680 million. ObsEva will not issue any new shares in connection with the listing in Switzerland.

Ernest Loumaye, CEO and Co-Founder of ObsEva said: "We are proud to initiate the listing at the SIX as it marks an important milestone for our company. The SIX Swiss Exchange is Europe's leading exchange for life sciences companies and Swiss institutional and private investors have developed a strong understanding of the healthcare sector. Our late-stage clinical pipeline offers numerous opportunities and is progressing well. Recent results demonstrate the efficacy of our therapies and confirm the potential therapeutic benefits."

Key data

Members of ObsEva's leadership team will open the market and ring the IPO bell today at market opening.

Copies of the listing prospectus can be obtained, free of charge in Switzerland for 12 months following the first day of trading, at the following address: ObsEva SA, 12 Chemin des Aulx, 1228 Plan-les-Ouates, Switzerland (+41 22 552 38 40 / IR@obseva.com